Virtual Tour
Media
NEWS
Contact Us
Patients
Neurology & Ophthalmology
CinnoVex
ReciGen
CinnoTec
Xacrel
TYALIa
Cinnomer
Oncology & Hematology
PegaGen
CinnaPoietin
ZakAria
Ablyze
CinnaStim
Pectuna
Xtramab
KidiPeg
Endocrinology & infertility
Cinnal-f
CinnaFact
CinnaTropin
Melitide
CinnoPar
Lixafert
Maciza
Autoimmune & Immunology
Zerafil
SpikoGen
Eldixia
CinnoRA
Healthcare Professionals
Neurology & Ophthalmology
CinnoVex
ReciGen
Cinnomer
Xacrel
TYALIa
CinnoTec
Oncology & Hematology
PegaGen
CinnaPoietin
KidiPeg
ZakAria
Ablyze
CinnaStim
Pectuna
Endocrinology & infertility
Cinnal-f
CinnaTropin
CinnaFact
CinnoPar
Melitide
Autoimmune & Immunology
CinnoRA
Zerafil
SpikoGen
Capabilities
Our Technology
Business Development
Our Manufacturing Sites
Research and Development
About Us
Presidential Note
About CinnaGen
Mission Statement
Policy
Management Team
Search
Virtual Tour
Media
NEWS
Contact Us
News
June2020
Researchers announced safety and effectiveness of ReciGen (interferon beta-1a 44 mcg manufactured by CinnaGen Co.) on COVID-19 patients
20June 2020
Monthly Arvhive
All News
Oct2016
Sept.2016
Sept.2018
Aug.2016
June2018
June2019
June2020
May2022
May2018
Mar.2018
Mar.2017
Feb.2018
Jan2017
Jan2020
Jan2019
Home
News: June2020
Back top Top
